NMN: what the human trials found, and what they have not

Before you read onResearch and educational information for adults, not medical advice. This entry explains one longevity term — what it means, why it matters and what the evidence says — and nothing here diagnoses, treats, cures or prevents any condition. Baseline labs come before anything, and your own physician has the final word. Longevity Bros offers coaching and written research protocols only — we do not sell, supply, source or ship any compound.

What it means

Nicotinamide mononucleotide is the molecule one step before NAD+ in the salvage pathway: the body converts it with a single enzyme (NMNAT). It is sold as a capsule or powder, typically 250–1,000 mg per day, and marketed on the strength of mouse studies showing improved endurance, insulin sensitivity and vascular function in old animals.

How oral NMN reaches cells is debated — it may be converted to NR in the gut first — but blood NAD+ rises either way.

Why it matters for longevity

If declining NAD+ drives part of ageing, replacing it cheaply would be a meaningful lever. NMN is the precursor with the largest marketing footprint and a US regulatory dispute (the FDA ruled in 2022 that it could not be sold as a dietary supplement because it is under investigation as a drug; enforcement has been uneven).

What the evidence says

Irie 2020: 10 Japanese men, single doses up to 500 mg, safe, blood NAD+ metabolites rose. Yoshino 2021 (Science): 25 postmenopausal women with prediabetes, 250 mg/day for ten weeks, muscle insulin sensitivity improved by about 25%, with no change in body composition, glucose or mitochondrial function. Yi 2023: 80 middle-aged adults, 300–900 mg/day for 60 days, blood NAD+ rose dose-dependently, six-minute walk improved modestly, no change in a blood-chemistry age score at 300 or 600 mg.

Those are the human data in full. Nothing on lifespan, disease incidence, cognition or sarcopenia; no trial longer than three months.

How to measure or use it

If trialled, the measurable endpoints used in the studies are fasting insulin / HOMA-IR, a walking or VO2max test and subjective energy — over 8–12 weeks against a baseline.
Quality varies widely between products; NMN degrades with heat and moisture, and independent testing has found underdosed and empty products.
It is not a substitute for the interventions that raise NAD+ with outcome data — training and body-fat control.

Mitochondria and energy — NMN and NR trials, tabulated
Supplements that have evidence — where NMN ranks
NAD+ (research page) — the injectable research compound, and what it is studied for

Frequently asked questions

Is NMN safe?

Short trials up to 1,250 mg/day for 4–12 weeks report no serious adverse effects. Long-term safety is untested, and there is a theoretical concern about feeding senescent or tumour cells.

Why was NMN banned in the US?

The FDA ruled in late 2022 that NMN is excluded from the dietary-supplement definition because it was being studied as a drug. It remains widely sold; the legal position is unsettled.

What dose was used in the trials?

250 mg/day in the insulin-sensitivity trial; 300–900 mg/day in the walking-distance trial. Higher doses have no evidence of extra benefit.

Your own protocol

Want this applied to your own numbers?

Fifteen minutes of intake, your labs, a human-reviewed protocol within about 24 hours, three documents, a free coach call and check-ins through the cycle. €399, follow-up included.

Build my protocol Book a 15-minute call